Prakt. lékáren. 2022; 18(2): 82-86 | DOI: 10.36290/lek.2022.017

Less common drug interaction and its solution demonstrated on the example of HIV patient from the perspective of clinical practice

Lukáš Bauer, Jana Gregorová
Oddělení klinické farmacie, Fakultní nemocnice Bulovka, Praha

Evaluation of drug interactions and offering the most suitable solution may be complicated in some cases. Pharmaceutical, pharmacodynamic and pharmacokinetic interactions should be considered in the interpretation. It is important to properly assess the potential of drug to interact not only at the metabolic level but also at the level of absorption, distribution and especially elimination. The article discusses the basic interactions of integrase inhibitors used in HIV patients. The solution of such an interaction is shown on the example from clinical practice.

Keywords: drug interactions, antiretroviral drugs, HIV, integrase inhibitors, metformin, clinical pharmacy.

Published: June 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bauer L, Gregorová J. Less common drug interaction and its solution demonstrated on the example of HIV patient from the perspective of clinical practice. Praktické lékárenství. 2022;18(2):82-86. doi: 10.36290/lek.2022.017.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Fletcher CV. Overview of antiretroviral agents used to treat HIV. UpToDate. [Internet] [Cited: 6. 2. 2022]. Available from: https://www.uptodate.com/contents/overview­‑of­‑antiretroviral­‑agents­‑used­‑to­‑treat­‑hiv.
    2. Hughes CA, Tseng A, Cooper R. Managing drug interactions in HIV­‑infected adults with comorbid illness. Canadian Medical Association Journal. 2015;187(1):36-43. Go to original source... Go to PubMed...
    3. Snopková S, Rozsypal H, Aster V, et al. Doporučený postup péče o dospělé infikované HIV a postexpoziční profylaxe infekce HIV. infekce.cz. [Internet] [Cited: 6. 2. 2022]. Available from: https://www.infekce.cz/DPHIV19.htm.
    4. Murínová I. Klinicky významné lékové interakce antiretrovirotik. Časopis lékařů českých. 2019;158(7-8):289-294. Go to PubMed...
    5. Státní ústav pro kontrolu léčiv. www.sukl.cz. [Internet] [Cited: 29. 1. 2022]. Available from: https://www.sukl.cz/modules/medication/search.php.
    6. Snopková S, Husa P. Současné možnosti antiretrovirové léčby. Remedia. 2015;25(5):356-363.
    7. Saumoy M, Quesada JLS, Martínez E, et al. LDL subclasses and lipoprotein­‑phospholipase A2 activity in suppressed HIV­‑infected patients switching to raltegravir: Spiral substudy. Atherosclerosis. 2012;225(1):200-207. Go to original source... Go to PubMed...
    8. Yagura H, Watanabe D, Ashida M, et al. Correlation between UGT1A1 polymorphisms and raltegravir plasma trough concentrations in Japanese HIV-1-infected patients. Journal of Infection and Chemotherapy. 2015;21(10):713-717. Go to original source... Go to PubMed...
    9. Belkhir L, Devaux CS, Elens L, et al. Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients. Scientific Reports. 2018;8(1):7359. Go to original source... Go to PubMed...
    10. Milburn J, Jones R, Levy JB. Renal effects of novel antiretroviral drugs. Nephrology Dialysis Transplantation. 2017;32(3):434-439. Go to PubMed...
    11. European medicines agency. www.ema.europa.eu. [Internet] [Cited: 30. 1. 2022]. Available from: https://www.ema.europa.eu/en/documents/assessment­‑report/vitekta­‑epar­‑public­‑assessment­‑report_en.pdf.
    12. Lindeman TA, Duggan JM, Sahloff EG. Evaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected Adults. Open Forum Infectious Diseases. 2016;3(2):ofw053. Go to original source... Go to PubMed...
    13. Castellino S, Moss L, Wagner D, et al. Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans. Antimicrobial Agents and Chemotherapy. 2013;57(8):3536-3546. Go to original source... Go to PubMed...
    14. Song I, Weller S, Patel J, et al. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. European Journal of Clinical Pharmacology. 2016;72(6):665-670. Go to original source... Go to PubMed...
    15. University of Liverpool. www.hiv­‑druginteractions.org. [Internet] [Cited: 30. 1. 2022]. Available from: https://www.hiv­‑druginteractions.org/.
    16. Toronto General Hospital. hivclinic.ca. [Internet] [Cited: 30. 1. 2022]. Available from: https://hivclinic.ca/wp­‑content/uploads/2019/06/Diabetes%20Medications_Eng.pdf.
    17. Straight Healthcare. www.straighthealthcare.com. [Internet] [Cited: 20. 1. 2022]. Available from: https://www.straighthealthcare.com/oct2-mate­‑illustration.html.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.